Compare Amphastar Pharmaceuticals Inc (AMPH) vs Zeta Global Holdings Corp (ZETA) Price & Performance

AMPH trades at $19.87, down 2.19% today, with a bullish technical signal from moving averages and ADX indicators. The company reported Q2 2026 EPS of $0.91, beating expectations, but missed in Q4 2025 and Q1 2026. Revenue for 2025 was $719.89M with a net income margin of 10.76%, while valuation ratios like P/E of 12.08 and EV/EBITDA of 6.57 suggest reasonable pricing. Recent news highlights growth from new product launches and ongoing FDA compliance efforts.

The outlook is mixed with growth opportunities from proprietary drugs and biosimilars, but risks include regulatory scrutiny and earnings volatility. Analyst sentiment is cautious with 25% buy ratings, reflecting concerns over execution and market pressures. Investors should weigh solid cash flow generation against competitive and regulatory headwinds for balanced exposure.

Zeta Global (ZETA) trades at $28.51, up 3.52% with strong technical momentum and bullish analyst sentiment. The stock shows robust revenue growth with 2026 projections reaching $1.6B and recent quarters consistently beating earnings estimates. Technical indicators signal bullish momentum with the current price approaching key resistance at $30, while fundamental metrics show improving profitability trends despite negative net margins.

The outlook remains positive with 73% analyst buy ratings and a $30.44 consensus target, representing 6.8% upside. Key risks include premium valuation (EV/EBITDA 95.89) and execution challenges amid aggressive growth targets. Recent AI partnerships and 20 consecutive beat-and-raise quarters support the growth narrative, though investors should monitor margin expansion and competitive pressures.